vitro biomap fibrosis panel Search Results


vitro biomap fibrosis panel  (Eurofins)
86
Eurofins vitro biomap fibrosis panel
Vitro Biomap Fibrosis Panel, supplied by Eurofins, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap+diversity+panel+plus/10__21203_slash_rs__3__rs___7539711_slash_v1-68-3-21
Average 86 stars, based on 1 article reviews
vitro biomap fibrosis panel - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
biomap panels  (DiscoverX corporation)
90
DiscoverX corporation biomap panels
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap Panels, supplied by DiscoverX corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap+systems/pmc07327036-109-11-10
Average 90 stars, based on 1 article reviews
biomap panels - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
biomap fibrosis panel  (AnaBios Corporation)
90
AnaBios Corporation biomap fibrosis panel
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap Fibrosis Panel, supplied by AnaBios Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap+fibrosis+panel/ppr0938624-300-5-30
Average 90 stars, based on 1 article reviews
biomap fibrosis panel - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
biomap  (Attagene Inc)
90
Attagene Inc biomap
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap, supplied by Attagene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap/pm36821828-353-82-84
Average 90 stars, based on 1 article reviews
biomap - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
biomap  (Eurofins)
86
Eurofins biomap
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap, supplied by Eurofins, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap/pm40998517-255-6-1
Average 86 stars, based on 1 article reviews
biomap - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
biomaps  (Inserm Transfert)
86
Inserm Transfert biomaps
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomaps, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomaps/pm40779164-203-18-17
Average 86 stars, based on 1 article reviews
biomaps - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
biomap  (Novartis)
86
Novartis biomap
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap+software/10__3791_slash_3445___v-89-16-17
Average 86 stars, based on 1 article reviews
biomap - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
discoverx biomap platform  (DiscoverX corporation)
90
DiscoverX corporation discoverx biomap platform
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Discoverx Biomap Platform, supplied by DiscoverX corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/discoverx+biomap+platform/pm35295225-289-7-6
Average 90 stars, based on 1 article reviews
discoverx biomap platform - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
biomap systems  (BioSeek Inc)
90
BioSeek Inc biomap systems
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap Systems, supplied by BioSeek Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap/pm19773588-26-23-28
Average 90 stars, based on 1 article reviews
biomap systems - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
biomap® profiling  (BioSeek Inc)
90
BioSeek Inc biomap® profiling
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap® Profiling, supplied by BioSeek Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/bioseek+profiles/pm26821304-71-14-17
Average 90 stars, based on 1 article reviews
biomap® profiling - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
biomap profiling experiments  (ScitoVation LLC)
90
ScitoVation LLC biomap profiling experiments
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap Profiling Experiments, supplied by ScitoVation LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap+profiling+experiments/pmc06635950-779-23-13
Average 90 stars, based on 1 article reviews
biomap profiling experiments - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
biomap assay  (Attagene Inc)
90
Attagene Inc biomap assay
Praziquantel effects in the <t>BioMAP</t> diversity panel. Profile <t>of</t> <t>PZQ</t> effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.
Biomap Assay, supplied by Attagene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vitro+biomap+fibrosis+panel/biomap+assay/pm36821828-277-7-36
Average 90 stars, based on 1 article reviews
biomap assay - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Praziquantel effects in the BioMAP diversity panel. Profile of PZQ effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.

Journal: Scientific Reports

Article Title: Investigating the antifibrotic effect of the antiparasitic drug Praziquantel in in vitro and in vivo preclinical models

doi: 10.1038/s41598-020-67514-4

Figure Lengend Snippet: Praziquantel effects in the BioMAP diversity panel. Profile of PZQ effects on the Diversity PLUS Panel. Human primary cells in the systems are used at early passage (4 or earlier) to minimize adaptation to cell culture conditions and preserve physiological signalling responses. The x-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the PZQ-treated sample over vehicle controls. The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log1- ratio| > 0.1). Biomarker key activities are described as modulated if these activities increase in some systems, but decrease in others. Cytotoxicitiy is indicated on the profile plot by a thin black arrow above the X-axis, and antiproliferative effects are indicated by a thick grey arrow. All cells are from a pool of multiple donors (n = 2–6), commercially purchased and handled according to the recommendations of the manufacturers. X-axis from left to right: CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD54/ICAM−1; CD62E/E−Selectin;CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; Proliferation; SRB; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD62P/P−selectin; CD87/uPAR; SRB; VEGFR2; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sPGE2; SRB; sTNF−alpha; CCL2/MCP−1; CD38; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; CXCL9/MIG; PBMC Cytotoxicity; Proliferation; SRB; B cell Proliferation; PBMC Cytotoxicity; Secreted IgG; sIL−17A; sIL−17F; sIL−2; sIL−6; sTNF−alpha; CCL2/MCP−1; CCL26/Eotaxin−3; CD106/VCAM−1; CD54/ICAM−1; CD90; CXCL8/IL−8; IL−1alpha; Keratin 8/18; MMP−1; MMP−3; MMP−9; PAI−I; SRB; tPA; uPA; CD54/ICAM−1; CD87/uPAR; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; HLA−DR; IL−1alpha; Keratin 8/18; MMP−1; MMP−9; PAI−I; SRB; tPA; uPA; CCL2/MCP−1; CD106/VCAM−1; CD141/Thrombomodulin; CD142/Tissue Factor; CD87/uPAR; CXCL8/IL−8; CXCL9/MIG; HLA−DR; IL−6; LDLR; M−CSF; PAI−I; Proliferation; Serum Amyloid A; SRB; CCL2/MCP−1; CD106/VCAM−1; CD54/ICAM−1; Collagen I; Collagen III; CXCL10/IP−10; CXCL11/I−TAC; CXCL8/IL−8; CXCL9/MIG; EGFR; M−CSF; MMP−1; PAI−I; Proliferation_72hr; SRB; TIMP−1; TIMP−2; CCL2/MCP−1; CD54/ICAM−1; CXCL10/IP−10; CXCL8/IL−8; CXCL9/MIG; IL−1alpha; MMP−9; PAI−I; SRB; TIMP−2; uPA; alpha−SM ; Actin; bFGF; CD106/VCAM−1; Collagen I; Collagen III; Collagen IV; CXCL8/IL−8; Decorin; MMP−1; PAI−I; SRB; TIMP−1; CCL2/MCP−1; CCL3/MIP−1alpha; CD106/VCAM−1; CD40; CD62E/E−Selectin; CD69; CXCL8/IL−8; IL−1alpha; M−CSF; sIL−10; SRB; SRB−Mphg.

Article Snippet: Using another model of established fibrosis, PZQ, tested in the DiscoverX BioMAP panels, modulated the expression of several cytokines but did not affect the expression of markers of myofibroblast activation and fibrosis related matrix activities such as αSMA and collagens.

Techniques: Cell Culture, Biomarker Assay, Transformation Assay, Generated, Concentration Assay